Monitor Ultragenyx's commercial launch execution and initial FAYUVI sales trajectory, as Abeona's royalty stream depends on product uptake. Also watch for any milestone payment disclosures in future SEC filings.
Price Chart
Executive Summary
Abeona Therapeutics issued a press release congratulating Ultragenyx on FDA approval of FAYUVI (UX111) for MPS IIIA, a gene therapy originally developed by Abeona as ABO-102 and out-licensed to Ultragenyx in 2022. The approval triggers potential commercial milestone payments and royalties for Abeona under the licensing agreement, representing a value-creation event for the company.
Key Facts
- FDA approved FAYUVI (rebisufligene etisparvovec-hopf) for MPS IIIA (Sanfilippo syndrome type A)
- FAYUVI originated from Abeona's research and was advanced as ABO-102 before out-licensing to Ultragenyx in May 2022
- Abeona is eligible to receive commercial milestone payments and royalties tied to future product sales under the licensing agreement
- Abeona's commercial-stage portfolio includes ZEVASKYN for RDEB and preclinical ABO-701 for PSMA-positive solid tumors
Financial Impact
Abeona eligible for commercial milestone payments and royalties on FAYUVI sales; specific amounts not disclosed
Risk Factors
- Commercial milestone and royalty amounts are undisclosed and may be modest relative to Abeona's market cap
- FAYUVI faces a small patient population (ultra-rare disease), limiting peak revenue potential
- Abeona's primary commercial focus remains ZEVASKYN, which has its own manufacturing and reimbursement risks
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3364649 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC 13D | $4.40 $4.31 | ▼ −2.05% | ▼ −2.76% | $4.31 (−2.05%) |
Sep 29, 2026 27d ago | Insider Cluster | $5.25 $5.01 | ▲ +4.57% | ▲ +4.75% | $4.31 (+17.90%) |
Sep 18, 2026 5w ago | Press Release | $5.57 $5.67 | ▲ +1.80% | ▲ +0.24% | $4.31 (−22.62%) |
Sep 15, 2026 5w ago | 8-K | $5.47 $5.39 | ▼ −1.55% | ▼ −1.88% | $4.31 (−21.21%) |
Aug 14, 2026 10w ago | Institutional Cluster | $5.94 $6.16 | ▲ +3.70% | ▲ +4.38% | $4.31 (−27.44%) |
Aug 13, 2026 10w ago | 8-K | $6.35 $5.99 | ▼ −5.67% | ▼ −5.48% | $4.31 (−32.07%) |
Aug 13, 2026 10w ago | Press Release | $6.35 $5.99 | ▼ −5.67% | ▼ −5.48% | $4.31 (−32.07%) |
Jul 9, 2026 15w ago | Insider Cluster | $6.98 $7.01 | ▲ +0.43% | ▲ +1.20% | $4.31 (−38.25%) |
Jun 15, 2026 19w ago | Insider Cluster | $5.65 $5.65 | · 0.00% | ▲ +1.25% | $4.31 (−23.72%) |
Jun 15, 2026 19w ago | Insider Cluster | $5.65 $5.65 | · 0.00% | ▼ −1.25% | $4.31 (+23.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers